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SUMMARY
Focal status epilepticus in POLG-related mitochondrial disease is highly refractory to
pharmacological agents, including general anesthesia. We report the challenges in
managing a previously healthy teenager who presented with de novo epilepsia partialis
continua and metabolic stroke resulting from the homozygous p.Ala467Thr POLG
mutation, the most common pathogenic variant identified in the Caucasian popula-
tion.We applied transcranial direct current stimulation (tDCS; 2 mA; 20 min) daily as
an adjunctive therapy because her focal seizures failed to respond to five antiepileptic
drugs at maximal doses. The electrical and clinical seizures stopped after 3 days of
tDCS. The second course of tDCS was administered for 14 days when the focal sei-
zures re-emerged a month later. The patient tolerated the procedure well. Following
4 months of hospitalization and prolonged community rehabilitation, our patient has
now returned to full-time education with support, and there is no report of cognitive
deficit. We have demonstrated the safety and efficacy of tDCS in treating refractory
focalmotor seizures caused bymitochondrial disease.
KEY WORDS: Focal seizures, Mitochondrial disease, Neurostimulation, Refractory
status epilepticus.
The clinical manifestations of mitochondrial disease are
heterogeneous,1 and seizures affect approximately a quarter
of adult patients.2 Refractory seizures have been long recog-
nized as one presenting feature of Alpers-Huttenlocher syn-
drome (AHS) in early childhood caused by pathogenic
variants in the POLG gene. More recently, juvenile-onset de
novo status epilepticus with or without hepatic failure has
been increasingly reported as a POLG-related mitochon-
drial disorder.3,4 Mixed seizure types, including generalized
convulsive seizures, epilepsia partialis continua (EPC),
myoclonus, and occipital seizures, are frequently observed.5
To date, there remains no effective treatment for POLG-
related epileptic encephalopathy. New therapeutic
approaches are desperately needed, given the carrier fre-
quency of common POLG mutations is prevalent (0.5–1%
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in the white European population) and high disease burden
and mortality observed in those in whom disease presents
with intractable epilepsy (median interval between disease
onset and death was 1 year).5
We have directly managed two cases of juvenile-onset
POLG disease from our region over the last 8 years. The
first case was a 17-year-old girl who died in the intensive
care unit despite maximal medical intervention in refractory
status epilepticus (for details see Data S1 and Figure S1).
Here we describe details of the second case, in whom,
despite a near fatal course, seizures stopped after applying a
noninvasive brain stimulation technique known as transcra-
nial direct current stimulation (tDCS).
Case report
A right-handed 15-year-old girl who was previously fit
and well, presented with a prolonged generalized tonic-clo-
nic seizure that required intubation and sedation in June
2015. Extubation was performed 48 h later, and jerking of
her left arm spreading periodically to involve the rest of her
body was noted. Metabolic, structural, infective, and
autoimmune causes of seizures were excluded with normal
routine laboratory studies, MRI head, lumbar puncture, neg-
ative anti-NMDAR and anti-VGKC antibodies, and MRI
pelvis. She was commenced on oral phenytoin and leve-
tiracetam and discharged home after several days of admis-
sion. A month later, she represented with five generalized
tonic-clonic seizures, preceded by a 2-day history of head-
ache, positive visual phenomena (colored circles), unsteadi-
ness, and hypersomnolence. Seizures were inadequately
controlled with a combination of phenytoin, levetiracetam,
sodium valproate, and pulses of methylprednisolone, and
treatment was escalated to general anesthesia. Following
extubation, the generalized seizures ceased, but she
remained encephalopathic and had frequent focal motor sei-
zures affecting the left arm. Electroencephalography (EEG)
confirmed electrical EPC arising from the right occipital
region. Sodium valproate was stopped as mitochondrial
disease was suspected at this stage. Her liver function was
normal.
The patient was transferred to the regional neurology
unit. She developed a new epileptic focus affecting the right
arm after transfer, and the MRI brain showed stroke-like
lesions (Figs. 1A–F). Direct sequencing of the POLG gene
(GenBank Accession number NM_002693.2) identified a
pathogenic homozygous c.1399G>A, p.(Ala467Thr) vari-
ant. Despite a cocktail of antiepileptic drugs (AEDs),
including lacosamide, perampanel, phenobarbitone,
Figure 1.
Axial view of MRI head. FLAIR-sequence (A–C) shows hyperintense lesions involving the right occipital lobe, right thalamus, and bilateral
parietal lobes. DWI sequence (D–F) shows restricted diffusion in the bilateral occipital lobes, right thalamus, and left parietal lobe (red
arrows) with increased ADCmap (not shown), suggestive of vasogenic edema.
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phenytoin, levetiracetam, and diazepam, EPC did not abate.
The patient was admitted to the pediatric intensive care unit
where the head was cooled and thiopentone administered
until a burst-suppression pattern was achieved on EEG. Fol-
lowing the withdrawal of thiopentone, recovery of con-
sciousness took 11 days. She was free of overt clinical
seizures for several days but had ongoing electrographic
focal status epilepticus and significant encephalopathy.
Debilitating EPC reemerged, affecting the right arm, leg,
and paraspinal muscles, and frequent myoclonic jerks (in-
cluding abdominal muscles) developed two weeks later.
Further EEG studies continued to detect epileptic discharges
arising from the posterior quadrant of the right hemisphere
that spread over to the left side at times; there was no appar-
ent EEG correlate with right upper and lower limb clonic
movements. These reemergent seizures were refractory to
AED therapy. Repeat administration of thiopentone was not
considered owing to the side effects of prolonged recovery
and risk of cardiorespiratory depression.
Concern over the patient’s deteriorating health urged us
to consider cathodal tDCS as an adjunctive treatment.
Methods for transcranial direct current stimulation
The clinical application of tDCS was approved as an
emergency compassionate therapeutic intervention by the
Newcastle upon Tyne Hospitals NHS Foundation Trust
(NuTH) New Interventional Procedure Committee (NIPC)
on a named patient basis. We obtained written consent from
the patient’s parents.
The location for the cathode was determined on the basis
of the stroke-like lesions identified on the serial MRI head
(Figs. 1A,D) and the electrode locations on the pre-tDCS
EEG at which phase-reversal of the epileptiform discharges
occurred (see Fig. 2A). In the case described, the location
approximated to T6, and therefore the cathode was placed
over the right occipito-tempero-parietal region (centered on
P4/T6; see Fig. 2B). The anode was applied to the left fore-
head (on a point approximating FP1). FP1 was chosen pri-
marily as the location for the anode because it was
contralateral and sufficiently anterior to the area of cortical
edema (and the epileptogenic focus), thus reducing the pos-
sibility of causing an increase in seizure activity. The long
axis of both electrodes was oriented in a coronal plane.
tDCS was delivered by a battery-powered (9V battery; IEC
6LR61) constant current stimulator (custom-built by the
Medical Physics Department, Newcastle upon Tyne Hospi-
tals) through a pair of 5 9 7 cm conductive rubber elec-
trodes covered in saline-soaked sponges (neuroConn,
Ilmenau, Germany).
To maximize the therapeutic effects of direct current
stimulation, a stimulus intensity of 2 mA was administered
for 20 min. To comply with the guidance of the NuTH
NIPC, the stimulation parameters chosen (2 mA and
20 min) were deemed to be the maximum safe parameters
used in children based on published literature.6
Results
The frequency of seizures was reduced significantly
during tDCS but returned to previous levels after tDCS
(see Figs. 2C,D). However, after 3 days of treatment, the
clinical seizures stopped altogether with the termination of
ictal discharges on the EEG (Fig. 2E). A month later, the
patient developed irregular twitching of abdominal mus-
cles and lower limbs, which her EEG captured as a clear
buildup of rhythmical sharp activity over the posterior
quadrant of the right hemisphere. We applied a 14-day
course of tDCS using the same protocol. She reported no
side effects other than a mild tingling or burning sensation
under the electrodes during the stimulation. Her AED
treatments were not adjusted during the period of tDCS
treatment.
The patient was discharged home after a total of 4 months
of hospitalization, and she received a prolonged period of
intense physical rehabilitation in the community. At the
most recent clinic review (12 months after discharge from
the hospital), she had returned to her studies with additional
educational support at school. She reports an unsteady gait
but can walk unaided. She has intermittent, brief sensory
seizures affecting the right side. Her AED regime includes
levetiracetam 1,750 mg twice daily, phenobarbitone 90 mg
twice daily, and perampanel 8 mg once daily. Clinical
examination showed subtle myoclonic jerks, poor visual
acuity bilaterally, restricted upgaze, astereognosis on the
right, areflexia, and an ataxic gait.
Discussion
Our patient’s clinical presentation and neuroimaging
changes are consistent with stroke-like episodes driven by
protracted seizures. The clinical management of acute
symptomatic seizures proved extremely challenging,
despite administration of multiple AEDs and general anes-
thetic agents, including thiopentone. However, we have
demonstrated that the adjunctive use of tDCS successfully
terminated the debilitating seizures. To our knowledge, this
is the first successful application of tDCS in the refractory
focal epilepsy caused by recessive POLGmutations.5
Transcranial direct current stimulation is a noninvasive
subthreshold method of modulating cortical excitability
using weak currents. First applied to the treatment of psychi-
atric disorders,7 there is now increasing interest in its poten-
tial therapeutic application to a range of neurological
disorders, including focal epilepsy.8 The effects of tDCS on
cortical excitability and the persistence of these effects are
dependent on the current density applied (i.e., current inten-
sity and electrode size), the polarity of the stimulus (cortical
excitability is reduced by cathodal stimulation and
increased by anodal stimulation), and the duration of DC
stimulation.9 Although the clinical behavior of seizures
observed in the context of mitochondrial diseases would
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suggest very different underlying mechanisms of epilepto-
genesis compared with other acquired or genetically deter-
mined epileptic syndromes, mitochondrial energy failure in
neurones and glia is likely to be an important contributor.
Cathodal tDCS will, as in all seizure disorders, reduce the
probability of sodium and calcium channel opening and thus
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the probability of action potential generation (and seizure
propagation) and, via long-term depression (LTD), reduce
the connectivity in epileptic networks.
Other putative mechanisms of action of tDCS include
depression of NMDA-receptor-mediated synaptic signals,
reduction of presynaptic inputs via postsynaptic hyperpolar-
ization, and alterations in NMDA receptor efficacy and
transmembrane protein migration.10,11 However, it should
also reduce the energetic demands on mitochondria by indi-
rect effects on spiking activity and possibly by direct effects
on glia12 and intracellular bioenergetics.13–15 To date, sev-
eral studies involving patients with refractory focal epilepsy
have provided some compelling evidence for the efficacy of
tDCS in reducing the frequency of clinical seizures.8,16,17
The technique of tDCS is emerging as a promising noninva-
sive, nonpharmacological, adjunctive treatment for refrac-
tory epilepsy owing to its low risk profile,8 low cost, and
ease of use compared to other surgical neurostimulation
techniques such as deep brain stimulation and vagus nerve
stimulation.
In summary, we report that tDCS was an effective adjunc-
tive therapy in a teenager who presented with refractory
POLG-related focal motor status epilepticus. Given the high
prevalence of epilepsy in patients with mitochondrial dis-
ease,2 we suggest that the application of tDCS in mitochon-
drial epilepsy warrants further evaluation in prospective
clinical studies.
Acknowledgments
Y.S.N. holds a NIHR clinical lectureship and was the recipient of
an MRC Centre for Neuromuscular Disease Clinical PhD studentship.
This work is supported by the Wellcome Centre for Mitochondrial
Research (203105), the Medical Research Council (MRC) Centre for
Translational Research in Neuromuscular Disease, Newcastle Univer-
sity Centre for Ageing and Vitality (supported by the Biotechnology
and Biological Sciences Research Council and MRC), Mitochondrial
Disease Patient Cohort (UK) (G0800674), the Lily Foundation, the UK
NIHR Biomedical Research Centre for Ageing and Age-Related Dis-
ease award to the Newcastle upon Tyne Foundation Hospitals NHS
Trust, and the UK NHS Highly Specialised Service for Rare Mito-
chondrial Disorders of Adults and Children. M.R.B. is employed by
the NHS, and research in his laboratory is funded by the UK MRC
and NIHR. We would like to thank the laboratory staff of the NHS
Highly Specialised Mitochondrial laboratory in Newcastle for molecu-
lar diagnostic studies.
Author contribution
Conception and design of the study: Y.S.N., R.M., and M.R.B. Acquisi-
tion of data: All authors. Analysis and interpretation of data: Y.S.N.,
H.V.R., M.L., V.R., R.W.T., D.M.T., G.S.G., R.M., and M.R.B. Drafting
the manuscript or figures: Y.S.N., H.V.R., R.M., and M.R.B. Critical
review and revision: All authors.
Disclosure
Nothing to report. We confirm that we have read the Journal’s position
on issues involved in ethical publication and affirm that this report is con-
sistent with those guidelines.
References
1. Gorman GS, Chinnery PF, DiMauro S, et al. Mitochondrial diseases.
Nat Rev Dis Primers 2016;2:16080.
2. Whittaker RG, Devine HE, Gorman GS, et al. Epilepsy in adults
with mitochondrial disease: a cohort study. Ann Neurol 2015;78:
949–957.
3. Uusimaa J, Hinttala R, Rantala H, et al. HomozygousW748Smutation
in the POLG1 gene in patients with juvenile-onset Alpers syndrome
and status epilepticus. Epilepsia 2008;49:1038–1045.
4. Visser NA, Braun KP, van den BerghWM, et al. Juvenile-onset Alpers
syndrome: interpretingMRI findings.Neurology 2010;74:1231–1233.
5. Anagnostou ME, Ng YS, Taylor RW, et al. Epilepsy due to mutations
in the mitochondrial polymerase gamma (POLG) gene: a clinical and
molecular genetic review. Epilepsia 2016;57:1531–1545.
6. Krishnan C, Santos L, Peterson MD, et al. Safety of noninvasive brain
stimulation in children and adolescents. Brain Stimul 2015;8:76–87.
7. Lippold OC, Redfearn JW. Mental changes resulting from the passage
of small direct currents through the human brain. Br J Psychiatry
1964;110:768–772.
8. Lefaucheur JP, Antal A, Ayache SS, et al. Evidence-based guidelines
on the therapeutic use of transcranial direct current stimulation (tDCS).
Clin Neurophysiol 2017;128:56–92.
9. Nitsche MA, Paulus W. Excitability changes induced in the human
motor cortex by weak transcranial direct current stimulation. J Physiol
2000;527(Pt 3):633–639.
10. San-Juan D, Morales-Quezada L, Orozco Garduno AJ, et al. Transcra-
nial direct current stimulation in epilepsy. Brain Stimul 2015;8:455–
464.
11. George MS, Aston-Jones G. Noninvasive techniques for probing neu-
rocircuitry and treating illness: vagus nerve stimulation (VNS), tran-
scranial magnetic stimulation (TMS) and transcranial direct current
stimulation (tDCS).Neuropsychopharmacology 2010;35:301–316.
12. Gellner AK, Reis J, Fritsch B. Glia: a neglected player in non-invasive
direct current brain stimulation. Front Cell Neurosci 2016;10:188.
13. Hashimoto M, Takeda Y, Sato T, et al. Dynamic changes of
NADH fluorescence images and NADH content during spreading
depression in the cerebral cortex of gerbils. Brain Res 2000;872:
294–300.
Figure 2.
Electrophysiology. Pretreatment EEG (A) showing continuous seizure activity over the right parieto-tempero-occipital region. Dia-
gram (schematic representation of international 10–20 system) indicating approximate locations of the cathode (blue) and anode (red)
used for DC stimulation (B). Graphical representation of the effect of tDCS on the patient’s seizures in a single session (C). The total num-
ber of myoclonic jerks was counted for each 15-s epoch of video-EEG and the mean seizure count for four consecutive epochs calculated
(jerks/minute) and plotted (error bars are standard deviations). The solid bar indicates when tDCS (2 mA; 20 minutes) was applied. The
data in (C) are further summarized in (D). In the bar graph, each bar plots the mean seizure frequency (jerks/second) before, during, and
after tDCS (error bars represent 1 standard deviation from the mean). Bonferroni corrected t tests confirmed the significant effect of
tDCS on seizure activity during tDCS. Posttreatment EEG (E), which confirmed that the seizure activity had ceased but some degree of
encephalopathy continued. Note the change of EEGmontage.
Epilepsia Open ILAE
Epilepsia Open, 3(1):103–108, 2018
doi: 10.1002/epi4.12094
107
POLG-related seizures, neurostimulation
14. Holandino C, Teixeira CA, de Oliveira FA, et al. Direct electric
current treatment modifies mitochondrial function and lipid body
content in the A549 cancer cell line. Bioelectrochemistry
2016;111:83–92.
15. Ardolino G, Bossi B, Barbieri S, et al. Non-synaptic mechanisms
underlie the after-effects of cathodal transcutaneous direct current
stimulation of the human brain. J Physiol 2005;568:653–663.
16. Assenza G, Campana C, Assenza F, et al. Cathodal transcranial direct
current stimulation reduces seizure frequency in adults with drug-resis-
tant temporal lobe epilepsy: a sham controlled study. Brain Stimul
2017;10:333–335.
17. San-Juan D, Espinoza Lopez DA, Vazquez Gregorio R, et al. Transcra-
nial direct current stimulation in mesial temporal lobe epilepsy and hip-
pocampal sclerosis. Brain Stimul 2017;10:28–35.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Data S1. Supplementary data.
Figure S1.Neuroimaging and electrophysiology.
Epilepsia Open, 3(1):103–108, 2018
doi: 10.1002/epi4.12094
108
Y. S. Ng et al.
